^
    Back
    Association details:
    Biomarker:IDH2 R140W + EGFR L858R
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P86.21 - Activating IDH Mutation as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC

    Published date:
    01/12/2021
    Excerpt:
    Patient 2 with IDH2_R140W and EGFR_L858R had PFS of 4.3 months and OS of 9.5 months after gefitinib treatment…